Phospho-VEGF Receptor 2 (Tyr951) Antibody [F15G14]

Catalog No.: F0653

    Application: Reactivity:
    • Lane 1: recombinant human GST-VEGF Receptor 2 (Val789-Val1356), Lane 2: recombinant human GST-VEGF Receptor 2 (Val789-Val1356) (λ phosphatase-treated)
    1/

    当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    キーポイント

    WB
    SDS-PAGE の分離ゲルの推奨濃度:5%
    転写条件(ウェット): 250 mA, 180 min

    使用情報

    Dilution
    1:1000
    Application
    WB
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Human, Mouse
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW
    230 kDa
    ポジティブコントロール Recombinant human GST-VEGF Receptor 2 (Val789-Val1356)
    ネガティブコントロール

    プロトコール

    WB
    Experimental Protocol:
     
    Sample preparation
    1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail, Phosphatase Inhibitor Cocktail),and homogenize the tissue at a low temperature.
    2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail, Phosphatase Inhibitor Cocktail) and put the sample on ice for 5 min.
    3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail, Phosphatase Inhibitor Cocktail) and put the sample on ice for 5 min.
    4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
    5. Remove a small volume of lysate to determine the protein concentration;
    6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
     
    Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
    2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
     
    Transfer membrane
    1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
    2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
    3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
    4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
    Recommended conditions for wet transfer: 250 mA, 180 min.
    ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
     
    Block
    1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
    2. Incubate the film in the blocking solution ( recommending 5% BSA solution) for 1 hour at room temperature;
    3. Wash the film with TBST for 3 times, 5 minutes each time.
     
    Antibody incubation
    1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight;
    2. Wash the film with TBST 3 times, 5 minutes each time;
    3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
    4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
     
    Antibody staining
    1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
    2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.

    Datasheet & SDS

    生物学的記述

    Specificity
    Phospho-VEGF Receptor 2 (Tyr951) Antibody [F15G14] detects endogenous levels of total VEGF receptor 2 protein only when it is phosphorylated at Tyr951.
    タンパク質の局在
    細胞接着、細胞膜、細胞質、細胞質小胞、小胞体、エンドソーム、細胞内膜系、細胞核、細胞外環境
    Uniprot ID
    P35968
    Clone
    F15G14
    Synonym(s)
    Vascular endothelial growth factor receptor 2; VEGFR-2; Fetal liver kinase 1 (FLK-1); Kinase insert domain receptor (KDR); Protein-tyrosine kinase receptor flk-1; CD309; KDR; FLK1; VEGFR2
    Background
    Phospho-VEGF Receptor 2 (Tyr951) represents a critical signaling node in the regulation of endothelial cell function and angiogenesis. VEGFR2, also known as KDR or Flk-1, is a receptor tyrosine kinase of the PDGFR family that mediates the effects of VEGF-A in vascular development and remodeling. Upon VEGF-A binding, VEGFR2 undergoes dimerization and autophosphorylation at multiple tyrosine residues, including Tyr951, which is located within the kinase insert domain adjacent to the activation loop. Phosphorylation at Tyr951 creates a docking site for the T-cell-specific adaptor protein (TSAd/VRAP/LAD), initiating the assembly of a VEGFR2-pY951-TSAd-Src signaling complex. This complex activates c-Src via phosphorylation at Tyr418 and dephosphorylation at Tyr527, thereby stimulating downstream PI3K-Akt pathways. The result is enhanced endothelial cell survival, increased vascular permeability, directed migration, and actin cytoskeletal reorganization necessary for cell motility. In tumors, TSAd and pY951 signaling are upregulated, thereby supporting abnormal vessel growth. Disruption of this pathway, through Y951F mutation, pY951-mimicking peptides, or TSAd silencing, impedes VEGF-A-induced endothelial migration, decreases tumor vascularization, and suppresses tumor growth in TSAd-deficient models.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください